Isabl
Isabl, formerly known as Isabl Technologies, is a healthcare diagnostics company spun off from Memorial Sloan Kettering Cancer Center in 2020, headquartered in New York City. The company specializes in genomic diagnostics for cancer, offering comprehensive analysis tools and a remote-first work culture.
Services
Isabl offers a comprehensive suite of diagnostic solutions centered around the genomic analysis of tumors. Their technology is designed to provide unprecedented clarity into tumor biology, aiding in treatment planning and precision diagnostics. The company's main service is a genetic test of tumors that analyzes the entire genome, facilitating highly personalized treatment plans. Additionally, Isabl provides a WGTS SaaS solution for comprehensive analysis of tumor genomes and transcriptomes, opening up opportunities for disease surveillance and biomarker discovery.
Founders
Isabl was spun off from Memorial Sloan Kettering Cancer Center in 2020, symbolizing its strong foundational roots in advanced cancer diagnostics and research. The company is named in memory of a loved one who lost her battle with cancer, highlighting its mission-driven approach to healthcare and diagnostics.
History
Founded in 2020 as a spin-off from Memorial Sloan Kettering Cancer Center, Isabl quickly established itself in the healthcare diagnostics industry. The company garnered significant attention and support, joining the Y-Combinator W20 batch and receiving funding from notable investors such as Two Sigma Ventures, BoxOne Ventures, and others. Isabl's technology, particularly its GxT platform, earned the FDA Breakthrough Device Designation, underscoring its potential impact in the field of cancer diagnostics.
Industry
Isabl operates within the healthcare industry, specifically focusing on diagnostics. The company emphasizes precision diagnostics, leveraging advanced genomics technology to provide detailed insights into tumor biology. This focus aligns closely with their mission to offer personalized treatment plans for cancer patients, enhancing the overall scope of patient health and care. Isabl's presence in the diagnostics sub-industry underscores its commitment to innovation and cutting-edge healthcare solutions.
Locations
Isabl maintains a remote-first culture, allowing team members to work remotely from various locations. The company also has an office in New York City, located at 175 Greenwich Street, Fl 38, New York, NY 10007. This office provides stunning views and fosters inspiring collaboration among team members. Despite its small team size of five, the company's influence spans the United States and Canada, reflecting its commitment to remote work and employee empowerment.
